Indian Write- Ups

Management
Post-Prandial Hyperglycemia
Ashok Kumar DasDirector, Professor & Head of Medicine, JIPMER
 
Nateglinide the drug belonging to the Meglitinide family is in early clinical trails worldwide. Its mechanism of the action & kinetics appear to differ from repaglinide.
 
Conclusions
 
Post-prandial hyperglycemia is an important risk factor in patients with diabetes & IGT. The pathogenesis of PPHG is probably multifactorial. Control of the post-prandial surge is essential in preventing morbidity & mortality. When diet & exercise fail to control PPHG, repaglinide may be considered. In the face of failure of these, insulin should be advocated & oral agents stopped. It is hoped that ongoing research into the pathophysiology & treatment of PPGH may yield better answers & potent armamentarum to tackle this troublesome condition.
 
References:
 
  1. Diabetes Control & Complications Trial Research Group. The effect of intensive treatment of diabetes on the development & progression of long-term complications a insulin-dependent diabetes mellitus N. Engl J. med 329 977- 86
  2. Kosaka K. Kuzuya T. Akanuma Y et al increase response after treatment overt maturity –onset diabetes is independent of the mode of treatment Diabetologia.1823-8,1989
  3. Consoli A Role of liver in pathophvsiology of NIDDM Diabetes Care 15(3), 436-41,1992
  4. Sacca L. Cicala B. Trimarco B. et al Differential effects of insulin on splanchnic & peripheral glucose disposal after an intravenous glucose load in man J Ohn Invest, 70; 117-26,1982
  5. De Fronzo R.A. Ferrannini E. Hendler R et al; Influence of hyperinsulinemia, hyperglycemia, & the route of glucose administration on splanchnic glucose exchange Proc. Natl. Acad. Sci., USA;A 15,5173-77,1978.
  6. Ferrannini E. Bjoorkman O. Riechard G et al. The disposal of an oral glucose load in healthy subjects, a quantitative study, Diabetes 34,580-88,1985
  7. McQahon M Marsh H. Rizza R. Comparison of the pattern of carbohydrate metabolism after ingestion of a glucose drink of a mixed meal. J. Clan Endocrinol. Metab 68,647-53,1989
  8. Jackson R. Roshania R. Hawa M et. Al Impact of glucose ingestion on hepatic & peripheral glucose metabolism in man an analysis based on simultaneous use of the forearm & double isotope techniques. J. Clan Endocrinol Metab 63 541- 49,1986
  9. Reaven G. Miller R. Study of the relationship between glucose & insulin response to an oral glucose load in men Diabetes 17 560-9,1968
  10. Pfeifer M.A., Haalter JB, Porte D Jr. Insulin secretion in diabetes mellitus. American journal of Medicine 70,579-88,1981
  11. Ahren B. Pacini G Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance American Journal of Physiology 273(41) E701-7,1997
  12. Osei K. Gaillard T. Schuster DP et al Pathogenetic mechanisms of impaired glucose intolerance & type 2 diabetes in African-American. The significance of insulin secretion, insulin sensitivity & glucose effectiveness Diabetes Care2003,396-404, 1997
  13. Toft I, Bonna K.H. Lindal S et al Insulin kinetics, insulin action & muscle morphology in lean or slightly overweight persons with impaired glucose tolerance Metabolism Clinical 8 Eperimental 4707;848-54,1998
  14. Gerich JE, Metabolic abnormalities in impaired glucose tolerance Metabolism Clinical 8 Experimental 46 (12 Suppl 1) 40-3,1997
  15. Tavridou A. Unwin NC, Laker MF et al Serum concentrations of vitamins A & E in impaired glucose tolerance Clinica Chemica Acta 26602;129-40,1997
  16. Green GM, Guan D, Schwartz JG et al Accelerated gastric emptying it glucose on Zucker type 2 diabetic rats role in postprandial hyperglycaemia Diabetologia 40(2)136-42,1997
  17. Frank JW, Saslow S.B. Camilleri M et al mechanism of accelerated gastric emptying of liquids, & hyperglycemia in patients with type II diabetes mellitus, Gastroenterology 109(3)755-65,1995
  18. Dinneen S. Afzaid A, Turk D et al Failure of glucagon suppression contributes to postprandial hyperglycemia in IDDM Diabetologia 38,337-43,1995
  19. Alzaid AA, Dinneen SF, Turk DJ et al; Assessment of insulin action & glucose effectiveness in diabetic & nondiabetic humans J. Clin Invest 94 2341-8,1994
  20. Stolk RP Bretler MMB. Ott A et la insulin cognitive function in an elderly population Diabetes Care;20 792-5,1997
  21. Avignon A Radauceannu A. Monnier L. Non fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20;1822-6,1997
  22. Pettit DJ, Knowler Wc, Lisse JR et al Development of retinopathy & proteinuria in relation to plasma glucose concentrations in Pima Indians Lancet 2, 1056-2,1980
  23. Teuscher A Schneil H. Wilson PW Incidence of diabetic retionopathy & relationship to baseline plasma glucose & blood pressure Diabetes Care, 11,246-51,1988
  24. De Veciana M. Major C.A. Morgan NA et al, Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy N. Engl J Med 333 1237-41,1995
  25. Donahue RP. Abbott RD, Reed DM et al Post challenge glucose concentration & coronary heart disease in men of Japanese ancestry Honolulu Heart Program Diabetes, 36,689-92,1987
  26. Fuller JH. Shipley MJ, Rose 6 et all Coronary heart disease risk & impaired glucose tolerance the Whitehall Study Lancet 1, 1373-6,1980
  27. Jackson CA, Judka JS Forrest RD, A Comparison of the relationship of the glucose tolerance test & the glycated hemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey Diabetes Res. Clin Pract. 17111-23,1992.
  28. Hanefield M. Temekove-kurktschiev T. The postprandial state & the risk of atherosclerosis, Diabetic Med. 4 Suppl 3 56-31,1997
  29. Fontbonne AM Eschwege EMI Insulin & carbovasular disease Paris Prospective study Diabetes Care 14-161-1998
  30. UK Prospective Diabetes Study (UKPDS) Group Intensive blood glucose control with sulphonyvureas or insulin compared with conventional treatment & risk of complications in patients with type 2 diabetes (UKPDS33) Lancet 352837-53,1998
  31. Russel JC Koesiag DG, Dolphin P J et al Beneficial effects of acarbose in the athersclerosis prone JCR La- Corpulent rat Metabollism42218-23;1999
  32. Patsch JR. Miesenbock G. Hoptewieser T Relation of triglyceride metabolism & coronary heart disease studies in the postprandial state Arterioselr thrown 121336-15,1992
  33. Brenelli SL. Gompos S.D. Saad MJ Viscocity of gums in vitro & their ability to reduce postprandial hyperglycemia in normal subjects Brazilian Journal of Medical & Biological Research 301947-40,1997
  34. Anderson JH Bruneile RL. Korvisto V.A. et al Reduction of postprandial hyperglycemia & frequency of hypoglycemia in IDDM patients on insulin-analog treatment Diabetes 46,265-70,1997.
  35. Anderson JH Bruneille RL. Keohane P et all Mealtime treatment with insulin analog improves postpranials hyperglycemia & hypoglycemia &hypoglycemia in patients with non-insulin, depdeted diabetes mellitus. Arch Intern Med. 157,1249-55,1997
  36. Holleman F. Schmitt II, Rottiers R. Rees A et al Reduced frequency of severe hypoglycemia & coma in well controlled IDDM patients treated with insulin lispro Diabetes Care:201827-32,1998
  37. Brunelle R.L. Llewelyn J. Vignati L et al, Humalog reduces the incidence of severe hypoglycemia in IDDM patients 16th International Diabetes Federation Congress 1386,1997
  38. Torlone E. Pampanellis. Lalli C et al Effects of the short acting insulin analog [lyst(828), pro(B29)] on postprandial blood glucose control in IDDM Diabetes Care 19,945-52,1996
  39. Kolterman OG, Moyses C. Colburn W. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amvin analogue Diabetes Care,18,1179-82,1995
  40. Rosenstock J. Whitehouse F. Schoenfeld Set al Effect or pramlintide on metabolic control & safety profile in people with type 1 diabetes. Diabetes 47 Suppl.A 88
  41. Bischoff H Pharmacology of alpha-glucosidase inhibition Eur J Clm Inves 246-10,1994
  42. Wolfenbuttel BH, Nijst L. Sels JP et al Effects of a new oral hypoglycemic agent repaglinide, on metabolic control in sulphonylurea-treated parents with NIDDM Eur J Clin Pharmacol. 45113-6,1993.
1  2  3  4   Top


Printer FriendlyPrinter Friendly

Home | About Us | Privacy | Feedback | Site Map | Contact Us

Copyright © 2007 Abbott India Limited. All Rights Reserved. Please read the Legal Notice for further details.